NCT00740805

ABT-888 (Velaparib) and Cyclophosphamide With Versus Without Doxorubicin in Treating Patients With Metastatic or Unresectable SolidTumors or Non-Hodgkin Lymphoma

Study identifier: NCT00740805
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

• Metastatic or unresectable disease
• Standard curative or palliative measures do not exist or are no longer effective
• Documented BRCA1 or BRC2 mutation, triple-negative breast cancer (defined as ER-negative, PR-negative, and HER2-negative, or patients who would benefit from a cyclophosphamide-based regimen

Type of study:

Phase I and Phase II

Treatment:

• Phase I – Group I: Patients receive oral ABT-888 twice daily on days 1-4 and cyclophosphamide IV over 60 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
• Phase I – Group II: Patients receive oral ABT-888 and cyclophosphamide IV as in group 1. Patients also receive doxorubicin hydrochloride IV over 15 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
• Phase II: Patients receive ABT-888, cyclophosphamide, and doxorubicin hydrochloride at the maximum tolerated dose determined in phase I.
  
  

Study site:

New Jersey

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey,  08903
Contact: Clinical Trials Office - Cancer Institute of New Jersey     732-235-8675   

Page updated 03/21/11

Web design by Rareheron Web Design